Epetraborole is under clinical development by AN2 Therapeutics and currently in Phase I for Burkholderia pseudomallei Infections (Melioidosis). According to GlobalData, Phase I drugs for Burkholderia pseudomallei Infections (Melioidosis) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Epetraborole LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epetraborole overview

Epetraborole is under development for the treatment of mycobacterium avium complex, or MAC, the most common type of NTM, mycobacterium abscessus, hepatic impairment and melioidosis. The drug candidate is administered as intravenous infusion and through oral route. It is a systemic antibiotic. It acts by targeting the bacterial enzyme leucyl tRNA synthetase. Leucyl tRNA synthetase is an alpha monomer. It is developed based on boron chemistry technology platform.

It was also under development for gram-negative bacterial infections including Enterobacteriaceae infections, Escherichia coli infections, Klebsiella pneumoniae infections and complicated urinary tract infections including acute pyelonephritis and intra-abdominal infections.

AN2 Therapeutics overview

AN2 Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for chronic, rare, and infectious diseases. The company is investigating epetraborole candidate, an oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. It is also evaluating epetraborole in treating Mycobacterium avium complex (MAC) lung disease and M. abscessus lung disease. AN2 Therapeutics drug discovery platform Boron binds on biological targets through a reversible covalent bond using traditional carbon-based molecules to discover drugs for infectious diseases. The company works in collaboration with Brii Biosciences to develop, manufacture, and commercialize epetraborole compounds in China, Hong Kong, Taiwan, and Macau. AN2 Therapeutics is headquartered in Menlo Park, California, the US.

For a complete picture of Epetraborole’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.